Zevra Therapeutics at ASHG 2026
Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website
Zevra Therapeutics brings 1 presentation to ASHG 2026 in Montréal, and exhibits at Booth 1302. Its program centres on rare-disease therapeutics and evidence from patient access programs at this meeting. Its presentation examines NPC1 genotypes in a US early access program for Niemann-Pick disease type C.
| Organization | ASHG 2026 Attendance |
|---|---|
Zevra Therapeutics Boston, Massachusetts | 1 presenter |
Zevra develops and commercializes therapeutics for rare diseases, serving patients with limited or no treatment options.
| Booth Exhibiting at Booth 1302 Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm Poster Fri Oct 23 2:30 pm Analysis of NPC1 Genotypes: Findings from the US Arimoclomol Early Access Program for Niemann-Pick Disease Type C Lysosomal diseasesBrain/nervous systemNervous system |
Instantly find 20 buyers from Zevra Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction